Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Pandion discovered a modified IL-2 molecule that outperformed competitors despite violating their initial thesis of tissue-tethered modulation. Anchor decisions around patient impact rather than founder attachment to validate pursuing unexpected scientific deviations.

Related Insights

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

The company's genesis was unconventional. It was founded by Bob Yant, a patient with a spinal cord injury, who proactively sought out leading researchers to translate promising science into therapies. This patient-driven model highlights an alternative pathway for biotech creation, where the 'problem' finds its 'solution' in academia.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

The decision to found Skeletalis wasn't driven by a single lab breakthrough. Instead, it was the convergence of two distinct observations: clinically seeing patients' fear of existing drug side effects, and academically noticing a major gap at conferences between advanced animal model research and its translation into new human therapies.

Unlike many assets discovered via platforms and then matched to an indication, Palisade's PDE4 inhibitor was specifically designed for Inflammatory Bowel Disease (IBD) from the start. This "disease-first" approach creates inherent mechanistic benefits and a stronger product narrative compared to repurposed drugs.

Founders must balance scientific conviction with market feedback. Kulkarni shares that his team abandoned pursuing certain indications that, while scientifically sound, failed to gain investor traction. This shows the critical need to pivot based on market signals, not just internal belief, to ensure continued funding and support.

Gene therapy companies, which are inherently technology-heavy, risk becoming too focused on their platform. The ultimate stakeholder is the patient, who is indifferent to whether a cure comes from gene editing, a small molecule, or an antibody. The key is solving the disease, not forcing a specific technological solution onto every problem.

While acknowledging that repurposing a failed drug feels like a "leap of faith," Declan Doogan stresses it's not a blind gamble. The successful pivot at Amarin was based on a "thorough and rigorous assessment of the science evidence based thinking," highlighting that radical strategic shifts must be built on a strong scientific foundation.

After Opthea's ophthalmology drug failed in trials, the company re-examined the underlying science of its VEGF-C/D mechanism instead of liquidating. This led to discovering a new application in a rare lung disease, proving that scientific assets can have value far beyond their initial intended use.

The most impactful life science ventures start with a clear, unmet clinical need and design research to solve it. This patient-centric approach provides direction and motivation, contrasting with the common model of finding an application for a recent scientific discovery.